---
title: "Brenntag partners with Budenheim to supply biopharma-grade phosphates under BYPHAR brand"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294196620.md"
description: "Brenntag has entered a strategic partnership with phosphate manufacturer Budenheim to expand the supply of high-purity, GMP-grade biopharma phosphates. Budenheim is the first co-brand partner for Brenntag’s global BYPHAR biopharma brand. Under this agreement, Budenheim’s biopharma phosphate portfolio will be sold globally under the BYPHAR brand in packs of 15 kg or less, while its PharSQ Pure line in larger packs will be distributed by Brenntag across Europe."
datetime: "2026-07-29T11:05:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294196620.md)
  - [en](https://longbridge.com/en/news/294196620.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294196620.md)
generator: "portal-rs"
---

# Brenntag partners with Budenheim to supply biopharma-grade phosphates under BYPHAR brand

-   Brenntag entered a strategic partnership with phosphate maker Budenheim to expand supply of high-purity, GMP-grade biopharma phosphates. \* Budenheim becomes the first co-brand partner for Brenntag’s global BYPHAR biopharma brand. \* Budenheim’s biopharma phosphate portfolio will be sold globally under BYPHAR in packs of 15 kg or less, targeting early-stage to commercial needs. \* Budenheim’s PharSQ Pure line in 25 kg or larger packs will be distributed by Brenntag across Europe. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brenntag SE published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BNR.DE](https://longbridge.com/en/quote/BNR.DE.md)

## Related News & Research

- [J.P. Morgan Keeps Their Sell Rating on Brenntag AG (0MPT)](https://longbridge.com/en/news/297133886.md)
- [Brenntag signs exclusive Eastern Europe distribution deal with Zeus Hygia Life Sciences](https://longbridge.com/en/news/297150091.md)
- [Brenntag AG (OTCMKTS:BNTGY) Sees Large Decline in Short Interest](https://longbridge.com/en/news/296096899.md)
- [Morgan Stanley Sticks to Their Sell Rating for Brenntag AG (0MPT)](https://longbridge.com/en/news/296148233.md)
- [Bayer says Japan approves sevabertinib for HER2-mutant NSCLC](https://longbridge.com/en/news/296745277.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**